Participated · Series A · Jun 2024

Canary Speech develops an API-first vocal biomarker platform that captures and analyzes speech data within seconds using patented real-time vocal analysis. Its technology is designed to screen for invisible illnesses such as anxiety, depression, and dementia by identifying behavioral and cognitive irregularities before current clinical screening standards or noticeable symptoms. The company offers applications across healthcare including contact centers, ambient clinical listening, remote patient monitoring, and annual wellness checks. Ambient listening tools are positioned to unobtrusively capture and analyze conversations in real time while documenting clinical notes. Led by CEO Henry O’Connell and based in Provo, UT, Canary emphasizes integrations that support provider workflows. The company intends to use recent funding to expand its team to support growth driven by AI advancements and healthcare demand for advanced tools.

Participated · Series A · May 2019

Pillo Health provides partner organizations an engaging in-home interface and a HIPAA-compliant technology platform to create customized voice-first health and wellness experiences. Led by co-founder and CEO Emanuele Musini, the company aims to help partners deliver care into the home and enhance patient connections to care teams. The company plans to use the new funding to continue development of its HIPAA-compliant platform and to build additional voice-first experiences for partners. Pillo is actively hiring in its Boston, MA and Genoa, Italy offices. The article reports the company raised $11M in a Series A to support these initiatives.

Participated · Series C · Feb 2018

Cota is a New York-based company led by CEO Miruna Sasu that provides oncology real-world data (RWD) and analytics using technology-supported human data abstraction methods. Its core product is an RWD platform and services that organize complex, fragmented patient data to support cancer research and drug development. The company expanded its data platform to cover nearly 2 million cancer patient lives, quadrupling data access in two years and adding full genomic data. Cota is integrating emerging data types including clinicogenomics, social determinants of health, and sexual orientation and gender identity (SOGI). It launched Vantage, a product that gives subscribers real-time access to broad, curated datasets that are proactively refreshed. The company also introduced services to support life sciences companies with FDA and EMA drug submissions, integrating RWD in R&D, enabling HEOR, and informing market-access strategies. Cota received an investment from Deerfield Management and existing investors; the amount was not disclosed, and the funds will be used to further expand its RWD platform and services to drive more efficient and inclusive drug development. Cota builds real-world evidence and data analytics products powered by its patented Cota Nodal Address (CNA), a digital classification methodology developed by physicians and data scientists to precisely categorize patient factors, diseases and therapies. The company enriches medical records to create research-grade data and pairs those datasets with analysis, visualization and management tools. Its real-world evidence sets are used by life science companies to broaden clinical trial applicability, improve measured efficacies and lower trial costs. Cota serves healthcare providers, payers and life sciences customers and intends to scale those solutions across those segments. The company is led by CEO John Hervey and executive chairman Andrew Pecora, M.D. Financially, Cota completed a $40M Series C to support its scaling plans. Cota builds research‑grade, real‑world data and precision analytics to measure cancer treatment outcomes using its patented Cota Nodal Address (CNA) digital classification system. The CNA transforms prognostically significant variables into a digital code to precisely categorize patient factors, diseases, and therapies for benchmarking, research, and value‑based care. Its customers include pharmaceutical companies, healthcare providers, and insurance companies, and it has partnerships with Novartis, Celgene, and data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine, and Horizon Healthcare. Cota’s CEO, Eric Schultz, says the company has seen strong revenue growth and rapid adoption of its products across multiple markets. A. Dana Callow, Jr. of Boston Millennia Partners is joining Cota’s board to provide guidance across provider, payer, life sciences, and regulatory environments. COTA (Cancer Outcomes Tracking and Analysis) operates a cloud-based platform that aggregates cancer patient data and performs real-time genetic sorting of certain cancers while providing outcome tracking and reporting to physicians. The platform aims to help tailor therapy decisions—for example, identifying breast cancer subtypes where chemotherapy is unlikely to help—thereby potentially reducing unnecessary treatment and costs. COTA plans to use new funding to expand development of its platform and to hire biostatisticians, outcome analysts, data support, and sales and marketing staff. The company intends to launch its first commercial product with the raised capital. Prior to this Series A, COTA received a seed round from private sources and RCCA, one of the largest oncology groups in the country.